炎症和炎症小体在肝脏疾病中的调控作用。
The Regulatory Roles of Inflammation and Inflammasomes in Liver Diseases.
机构信息
Department of Life Sciences, Kyonggi University, Suwon 16227, Republic of Korea.
出版信息
Int J Mol Sci. 2024 Sep 12;25(18):9864. doi: 10.3390/ijms25189864.
Abstract
Inflammation is an innate immune response that protects our body from various pathogens and cellular dangers [...].
摘要
炎症是一种先天免疫反应，可保护我们的身体免受各种病原体和细胞危险的侵害。
相似文献
1
The Regulatory Roles of Inflammation and Inflammasomes in Liver Diseases.炎症和炎症小体在肝脏疾病中的调控作用。
Int J Mol Sci. 2024 Sep 12;25(18):9864. doi: 10.3390/ijms25189864.
2
Inflammation unleashed: The role of pyroptosis in chronic liver diseases.炎症大爆发：细胞焦亡在慢性肝脏疾病中的作用。
Int Immunopharmacol. 2024 Nov 15;141:113006. doi: 10.1016/j.intimp.2024.113006. Epub 2024 Aug 29.
3
Basic and Clinical Advances in Chronic Liver Inflammation.慢性肝脏炎症的基础与临床进展
Mediators Inflamm. 2016;2016:1571457. doi: 10.1155/2016/1571457. Epub 2016 Feb 24.
4
Innate immune response and hepatic inflammation.固有免疫反应与肝脏炎症
Semin Liver Dis. 2007 Nov;27(4):339-50. doi: 10.1055/s-2007-991511.
5
Inflammasome: A Double-Edged Sword in Liver Diseases.炎症小体：肝脏疾病的双刃剑。
Front Immunol. 2018 Sep 25;9:2201. doi: 10.3389/fimmu.2018.02201. eCollection 2018.
6
Editorial. Inflammasomes--In Health and Diseases.社论。炎性小体——健康与疾病
Inflamm Allergy Drug Targets. 2015;14(2):66. doi: 10.2174/187152811402160416002851.
7
Inflammasomes contributing to inflammation in arthritis.炎性小体在关节炎炎症中的作用。
Immunol Rev. 2020 Mar;294(1):48-62. doi: 10.1111/imr.12839. Epub 2020 Jan 16.
8
Caspase-11 Non-Canonical Inflammasome: Emerging Activator and Regulator of Infection-Mediated Inflammatory Responses.半胱天冬酶-11 非经典炎性小体：感染介导炎症反应的新兴激活剂和调节剂。
Int J Mol Sci. 2020 Apr 15;21(8):2736. doi: 10.3390/ijms21082736.
9
Inflammasomes in liver diseases.炎症小体与肝脏疾病。
J Hepatol. 2012 Sep;57(3):642-54. doi: 10.1016/j.jhep.2012.03.035. Epub 2012 May 23.
10
Editorial of Special Issue "Regulatory Roles of Inflammasomes in Human Diseases".专刊编辑寄语：炎症小体在人类疾病中的调控作用
Int J Mol Sci. 2021 Mar 16;22(6):3008. doi: 10.3390/ijms22063008.
本文引用的文献
1
Pharmacological potential of ginseng and ginsenosides in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.人参及人参皂苷在非酒精性脂肪性肝病和非酒精性脂肪性肝炎中的药理潜力
J Ginseng Res. 2024 Mar;48(2):122-128. doi: 10.1016/j.jgr.2023.11.003. Epub 2023 Nov 14.
2
Flavonoids with Inhibitory Effects on NLRP3 Inflammasome Activation from .从 中提取的具有抑制 NLRP3 炎性小体激活作用的类黄酮。
J Nat Prod. 2020 Oct 23;83(10):2950-2959. doi: 10.1021/acs.jnatprod.0c00478. Epub 2020 Sep 29.
3
Toward targeting inflammasomes: insights into their regulation and activation.针对炎症小体：对其调控和激活的深入了解。
Cell Res. 2020 Apr;30(4):315-327. doi: 10.1038/s41422-020-0295-8. Epub 2020 Mar 9.
4
Flavonoids interfere with NLRP3 inflammasome activation.黄酮类化合物会干扰NLRP3炎性小体的激活。
Toxicol Appl Pharmacol. 2018 Sep 15;355:93-102. doi: 10.1016/j.taap.2018.06.022. Epub 2018 Jun 28.
5
Role of inflammatory response in liver diseases: Therapeutic strategies.炎症反应在肝脏疾病中的作用：治疗策略。
World J Hepatol. 2018 Jan 27;10(1):1-7. doi: 10.4254/wjh.v10.i1.1.
6
Innate immune recognition.固有免疫识别
Annu Rev Immunol. 2002;20:197-216. doi: 10.1146/annurev.immunol.20.083001.084359. Epub 2001 Oct 4.
Zotero 插件